The Global Health Body Sounds Alert Over Severe Scarcity of Weight-Loss Injections
Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy can access them, caution the global health agency as it issues its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable access to GLP-1 medication.
Per projections, more than two billion are projected to be obese by 2030 unless action is taken.
"Our new guidelines acknowledges that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are major hurdles to widespread availability to the injections that can assist patients in reducing significant weight, explains the organization.
GLP-1 Therapy Shortage
Despite the current best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation urges countries and companies to expand access, by strategies including patent sharing.
A patent on the active ingredient – the core component of the drug Wegovy – is due to expire in multiple nations in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so individuals consume fewer calories.
Individuals commonly begin shedding pounds within a few weeks of beginning the regular doses.
Evidence suggests users may regain a significant portion within a year of discontinuing the drug, as their usual food cravings resume.
Being carrying excess weight raises your likelihood for developing health problems, such as diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
